SLC5A2 and type 2 diabetes mellitus: Initially approved for type 2 diabetes mellitus, SGLT2 inhibitors were subsequently found to reduce HF hospitalizations and cardiovascular death, prompting investigation into their use in patients with HF and chronic kidney disease.